qfx

Apparently, back in February – February! – BLKBRD decided Hims & Hers wasn’t for them anymore. They offloaded 318,666 shares. 318,666! Who even counts that high? It’s just… excessive. And now we’re all supposed to care because it moved the market? It’s like they’re intentionally trying to manufacture drama. The transaction value? $18.07 million. Again with the sevens! It’s always the sevens. Net change? Also $18.07 million. They just… really wanted to emphasize the $18.07 million. It’s… unsettling.

Enter Steven Cohen, a name that resonates with a particular brand of Wall Street acumen. His Point72 Asset Management, a fund that doesn’t merely generate returns but curates them, has recently taken a position in Abivax (ABVX +5.03%), a French biotechnology firm. Over the past twelve months, Abivax’s shares have performed a rather flamboyant ascent, a stratospheric leap of over 1,600%. Is this a siren song for the discerning investor, or merely a particularly gaudy bubble waiting to burst? The question, as always, is deliciously complex.

Nvidia. Just saying the name feels…dangerous. It’s become a religion, hasn’t it? They’re not just making graphics cards anymore; they’re building the infrastructure for the future, the neural networks that will either save us or enslave us. AI. The buzzword that’s got everyone frothing at the mouth. And Nvidia? They’re shoveling money into the vault while the rest of us scramble for scraps. 77% revenue growth? That’s not a growth rate; that’s a goddamn rocket launch. And yet, trading at just 21.9 times forward earnings? It’s INSANE. The market is SLEEPING. This isn’t a stock; it’s a goddamn anomaly. A glitch in the matrix. And I intend to exploit it.

This brings their stake to a noteworthy 14.37% of reportable 13F assets – a fraction, certainly, but one that suggests a conviction bordering on affection. A portfolio, like a well-composed sentence, benefits from a carefully chosen emphasis. Let us observe their top five holdings, a little constellation of financial preference:

Analysts are predicting more growth, of course. 49% revenue growth, 53% EPS growth. Sounds impressive, right? It’s like saying a pigeon can fly. But at 140 times forward earnings? And 50 times sales? That’s not an investment, that’s a dare! You’re betting the farm on a hunch. A very expensive hunch. So, before you mortgage the house, let’s talk about a company that might actually offer a little…sanity. A little value. We’re switching gears, people. From the shadowy world of data mining to…chips!

This morning’s announcement – a proposed sale of $350 million in convertible notes – was not, in itself, unexpected. Yet, it landed with the force of a confession. CRISPR Therapeutics, a fledgling enterprise built on the audacious promise of gene editing, requires sustenance. Funds must be procured to fuel the relentless engine of research and development. The terms, however – the potential dilution of existing shareholder value – reveal a deeper truth: the market demands not merely innovation, but immediate gratification. It is a cruel mistress, this market, perpetually oscillating between hope and despair.

Okay, so robots. Fancy, aren’t they? Intuitive Surgical, the big name in robotic-assisted surgery (RAS), has had a couple of things to contend with. Tariffs, naturally. Because everything is always more complicated than it needs to be. And then Medtronic decided to have a go with their Hugo system. Competition. It’s the free market, darling. But honestly, the Hugo system isn’t going to dethrone the da Vinci system anytime soon. It’s like comparing a slightly enthusiastic hamster to a majestic eagle. Still, one can’t be complacent.